


Tubulin polymerization-IN-25

Cat. No.:	HY-149016
CAS No.:	2490538-46-8
Molecular Formula:	C ₂₄ H ₁₈ N ₂ O ₃ S
Molecular Weight:	414.48
Target:	Microtubule/Tubulin; Farnesyl Transferase
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Tubulin polymerization-IN-25 (compound 17f) is a dual inhibitor of tubulin polymerization and farnesyl transferase (FTase) with IC ₅₀ s of 1.11 μM and 0.39 μM, respectively. Tubulin polymerization-IN-25 displays cytotoxicity and excellent antitumor activity ^[1] .																
IC₅₀ & Target	IC ₅₀ : 1.11 μM (Tubulin); 0.39 μM (FTase) ^[1]																
In Vitro	<p>Tubulin polymerization-IN-25 (compound 17f) is a dual inhibitor (MTI-FTI hybrids) acting on tubulin polymerization and on FTase^[1].</p> <p>Tubulin polymerization-IN-25 (10 μM, 48 h) inhibits cells growth and induces cell cytotoxicity on multiple cancer cell lines^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Leukemia cells: SR, CCRF-CEM, K-562; lung cancer cell CCRF-CEMNCI-H522; melanoma cell M14</td> </tr> <tr> <td>Concentration:</td> <td>10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell growth.</td> </tr> </table> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>NCI-H522 (lung cancer), COLO-205 and HT29 (colon cancer), SF-539 (human glioblastoma), MDA-MB-435 (melanoma), OVCAR-3 (ovarian cancer) and A498 (renal cancer)</td> </tr> <tr> <td>Concentration:</td> <td>10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Induced cell cytotoxicity.</td> </tr> </table>	Cell Line:	Leukemia cells: SR, CCRF-CEM, K-562; lung cancer cell CCRF-CEMNCI-H522; melanoma cell M14	Concentration:	10 μM	Incubation Time:	48 hours	Result:	Inhibited cell growth.	Cell Line:	NCI-H522 (lung cancer), COLO-205 and HT29 (colon cancer), SF-539 (human glioblastoma), MDA-MB-435 (melanoma), OVCAR-3 (ovarian cancer) and A498 (renal cancer)	Concentration:	10 μM	Incubation Time:	48 hours	Result:	Induced cell cytotoxicity.
Cell Line:	Leukemia cells: SR, CCRF-CEM, K-562; lung cancer cell CCRF-CEMNCI-H522; melanoma cell M14																
Concentration:	10 μM																
Incubation Time:	48 hours																
Result:	Inhibited cell growth.																
Cell Line:	NCI-H522 (lung cancer), COLO-205 and HT29 (colon cancer), SF-539 (human glioblastoma), MDA-MB-435 (melanoma), OVCAR-3 (ovarian cancer) and A498 (renal cancer)																
Concentration:	10 μM																
Incubation Time:	48 hours																
Result:	Induced cell cytotoxicity.																

REFERENCES

[1]. Iuliana-Monica Moise, et al. Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity. *Bioorg Chem.* 2020 Oct; 103: 104184.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA